S-1/A: Mangoceuticals Navigates Losses, Dilution, and Legal Challenges

Mangoceuticals, Inc. reports significant net losses and declining revenues for recent periods, while pursuing strategic alternatives and facing substantial dilution from ongoing capital raises and related party transactions.

Summary

• Mangoceuticals, Inc. (MGRX) focuses on men's wellness products and services via a telemedicine platform, including compounded products (Mango ED, Grow, Mojo, Slim) and an FDA-approved oral Testosterone Replacement Therapy (Prime).
• The company reported a net loss of $7,618,776 for the three months ended September 30, 2025, a significant increase from $1,999,694 for the same period in 2024.
• Revenues decreased to $84,246 for the three months ended September 30, 2025, from $133,368 in the prior year, primarily due to issues with the transition to a new telehealth platform.
• For the nine months ended September 30, 2025, the net loss was $17,874,085, up from $6,758,630 in the prior year, driven by decreased revenue and increased general & administrative expenses, and significant stock-based compensation.
• Stock-based compensation dramatically increased to $6,601,793 for the three months ended September 30, 2025, from $567,619 in the prior year, and to $10,767,717 for the nine months ended September 30, 2025, from $1,881,464 in the prior year.
• The company had a working capital deficit of $0.2 million as of September 30, 2025, and an accumulated deficit of $37.8 million.
• Management believes additional funding is required to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The company is conducting Phase II clinical trials for patented respiratory illness prevention technology, with studies anticipated to be completed in Q1 2026.
• A Master Distribution Agreement for Dermytol (plant-based formulations for skin issues) was entered into, with operations expected to commence in Q2 2026.
• The company settled a lawsuit with Eli Lilly and Company for $20,000 and agreed to stop marketing Tirzepatide-based TRIM products on its website.
• An arbitration action was brought by Boustead Securities, LLC, claiming over $1,000,000 in fees and warrants for financial advisory services, which the company intends to vigorously defend.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with rapidly increasing net losses, declining revenues, and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern. Extensive related party transactions and ongoing dilution risks further compound the negative outlook, despite some product development efforts.

Positives

• The company is actively developing and marketing a range of men's wellness products (Mango ED, Grow, Mojo, Slim) and an FDA-approved TRT product (Prime).
• New product pipeline includes Dermytol for hyperpigmentation (expected Q2 2026 launch) and patented respiratory illness prevention technology (Phase II trials ongoing).
• The company utilizes a sublingual delivery system for its compounded products, which is believed to offer faster drug absorption and potential competitive advantages.
• The integrated technology platform connects consumers to healthcare professionals and pharmacies, aiming for cost advantages and efficiencies.
• Subscription plans are offered for recurring revenue, providing predictability and convenience for customers.
• Cash on hand increased to $481,281 as of September 30, 2025, from $58,653 as of December 31, 2024, due to financing activities.

Negatives

• The company has a limited operating history and has generated only limited revenues to date, with no assurance of future commercial revenues.
• Recurring net losses have been experienced since inception, with a net loss of $17,874,085 for the nine months ended September 30, 2025, significantly higher than $6,758,630 for the same period in 2024.
• Revenues are declining, with $361,661 for the nine months ended September 30, 2025, compared to $510,626 for the same period in 2024, mainly due to platform transition issues.
• The accumulated deficit has grown substantially to $37.8 million as of September 30, 2025, from $20.0 million as of December 31, 2024.
• The company's current capital resources are not expected to be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Significant reliance on related party transactions, including an exclusive agreement with Epiq Scripts, LLC, which is 52% owned and controlled by the CEO, Jacob D. Cohen.
• Compounded products are not FDA-approved and have not undergone FDA clinical trials, posing potential safety risks and regulatory challenges.
• The company faces intense competition from larger pharmaceutical companies and other wellness providers with greater resources and brand recognition.
• The stock price has been highly volatile, trading as high as $65.55 and as low as $0.52 per share since its IPO.
• The Eli Lilly lawsuit settlement required a $20,000 cash payment and cessation of marketing for certain products.
• An arbitration action by Boustead Securities, LLC, claims over $1,000,000 in fees and warrants, which could result in significant costs.

Risks

• Need for additional funding, which may not be available on favorable terms or at all, leading to potential curtailment of business plans or significant dilution to shareholders.
• Limited operating history and difficulty for investors to evaluate the business or forecast industry trends in a relatively new consumer product segment.
• Risk that the FDA may determine the compounding of products does not fall within the exemption from the FFDCA Act provided by Section 503A, potentially prohibiting sales.
• Significant reliance on related party transactions and relationships, which may not be on arm's-length terms and could present conflicts of interest.
• Epiq Scripts, the related party pharmacy, is not licensed in all 50 states, limiting product sales and growth potential.
• The Master Services Agreement with Epiq Scripts does not address product liability claims, potentially forcing the company to seek indemnification or contribution through costly litigation.
• The CEO, Jacob D. Cohen, has multiple professional obligations and significant voting control over Mango & Peaches Corp. (which holds substantially all company assets), potentially limiting shareholder influence and creating conflicts of interest.
• Potential competition from existing executive officers after their employment, subject to non-compete terms, which could negatively impact profitability.
• Risk of intellectual property infringement or misappropriation claims, which could be costly to defend and limit product sales.
• The telehealth business of contracted providers could be adversely affected by ongoing legal challenges or new state restrictions on telehealth services.
• Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection could result in significant liability or reputational harm.
• Product liability claims due to potential side effects of non-FDA approved compounded products, which could exceed insurance coverage and lead to substantial damages or recalls.
• Disruptions in data and information systems could harm reputation and business operations, especially given reliance on third-party hosting and payment processing.
• Fluctuations in tax obligations and effective tax rate could adversely affect financial condition.
• Economic downturns, high inflation, and increasing interest rates could limit consumer demand for discretionary products and affect access to capital.
• Volatility in the common stock price and significant dilution from future equity offerings, warrant exercises, and convertible securities.
• No guarantee of continued listing on the Nasdaq Capital Market if listing standards (e.g., stockholders' equity, market value, stock price) are not met.
• Risk of not successfully commercializing Pharmaceutical Products or future men's wellness products due to intense competition and inability to scale operations fast enough.
• The 6% Series C Convertible Cumulative Preferred Stock includes a liquidation preference of $20 per share, totaling $19.6 million, which is payable before common stockholders in a liquidation event.

Future Outlook

The company plans to continue marketing and management strategies, provide quality products with excellent customer service, and expand operations organically or through acquisitions in the technology, health, and wellness space. This includes ongoing technology enhancements to its platform, further development and marketing of men's health and wellness products, and identifying strategic acquisitions. Additional funding will be sought through debt or equity offerings, or strategic transactions, which may cause significant dilution to existing shareholders.

Management Comments

• Management believes that the faster the company scales its operations, the lower its cost of sales will be, due to economies of scale.
• Management believes that the alternative sublingual delivery methods for compounded products are a major competitive advantage.
• The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders in evaluating strategic alternatives.
• Management believes that the company can conduct truthful and non-misleading promotional activities with limited claims that do not require substantial evidence from clinical trials.

Industry Context

The company operates in the highly competitive and rapidly evolving health, wellness, and telemedicine industries. The global erectile dysfunction drugs market was valued at $3.63 billion in 2020, projected to contract to $2.95 billion by 2028, while the U.S. market is expected to grow at a 7.4% CAGR through 2030. The hair loss prevention products market was valued at $23.6 billion in 2021, projected to reach $31.5 billion by 2028. The global male hypogonadism market was $3.1 billion in 2020, projected to reach $5.1 billion by 2030. The semaglutide market size grew from $20.54 billion in 2023 to $23.07 billion in 2024, with projections to reach $36.87 billion in 2028. The company competes with larger players like Hims & Hers Health, Inc., Roman, Henry Meds, Pfizer (Viagra), Lilly (Cialis), Merck (Propecia), Johnson & Johnson (Rogaine), and Novo Nordisk (Ozempic, Wegovy).

Comparison to Industry Standards

• The company's compounded ED products are positioned against larger pharmaceutical companies offering branded drugs like Viagra (Pfizer) and Cialis (Lilly ICOS LLC), and their generic forms.
• Mango GROW competes with Merck & Co.'s Propecia and Johnson & Johnson's Rogaine, which are well-known branded hair loss products.
• Mango SLIM competes with Novo Nordisk's branded GLP-1 products like Ozempic and Wegovy.
• The company believes its sublingual product delivery system offers a competitive advantage over traditional pill or injectable formats offered by larger competitors.
• The company's compounded products, unlike FDA-approved drugs, have not undergone the FDA's clinical trial protocol, which is a standard for safety and efficacy in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• Eli Lilly and Company filed a complaint on October 31, 2024, alleging false and misleading advertising for the company's TRIM product, seeking declaratory judgment, injunction, corrective advertising, damages, and attorneys' fees. The company settled this on June 23, 2025, by paying $20,000 and agreeing to stop marketing Tirzepatide-based TRIM products.
• Boustead Securities, LLC initiated an arbitration action with FINRA on February 18, 2025, claiming over $1,000,000 in fees and warrants for financial advisory services. The company believes the claim lacks merit and intends to vigorously defend it.
• A Compromise Settlement Agreement and Mutual Release was entered into on May 5, 2025, with 1800 Diagonal Lending, LLC, settling claims against the company and Jacob D. Cohen by issuing 62,500 shares of restricted common stock.

Related Party Transactions

• Epiq Scripts, LLC: The company has an exclusive Master Services Agreement and Consulting Agreement with Epiq Scripts, LLC, a compounding pharmacy that is 52% owned and controlled by Jacob D. Cohen, the CEO. Epiq Scripts provides pharmacy and compounding services, and the company pays fixed rate fees and a 1% Non-Use Fee if services are transferred to another provider in a Current Jurisdiction. These agreements were assigned to Mango & Peaches Corp. on January 30, 2025.
• Jacob D. Cohen (CEO): Holds 52% ownership and control of Epiq Scripts, LLC. Received increased compensation, including a base salary of $420,000/year, a $10,000/month office allowance, and a $5,000/month car allowance. Was issued 4,892,906 common shares and 100 Series A Super Majority Voting Preferred Stock of Mango & Peaches Corp., giving him 75.2% voting control over the subsidiary that holds substantially all company assets. Also received 200,000 shares of common stock as a one-time grant on April 10, 2025, and 500,000 shares on September 9, 2025, plus options to purchase 2,000,000 shares on September 9, 2025.
• Cohen Enterprises, Inc.: Owned and controlled by Jacob D. Cohen. Provided loans to the company totaling $150,000 in March and April 2024, which were later formalized into a promissory note and sold to a third party.
• Ronin Equity Partners: Owned and controlled by Jacob D. Cohen. Provided a $37,500 loan to the company in March 2024, which was repaid in October 2024.
• The Tiger Cub Trust: Controlled by Jacob D. Cohen. Provided a $100,000 promissory note to the company on May 2, 2025, bearing 18% interest, later amended to be convertible into common stock at $1.785 per share, and granted warrants to purchase 50,000 shares.
• LT Global Practice Management: Owned by the wife of Jacob D. Cohen. Entered into a service agreement on January 28, 2025, to provide virtual professionals at rates between $1,800 to $3,500 per professional per month.
• The Loev Law Firm, PC: David M. Loev, the managing partner, is the brother-in-law of Jacob Cohen. Issued 100,000 shares for legal services rendered on September 16, 2025.
• Consultants who are also Epiq Scripts employees: Sultan Haroon, John Helfrich, Justin Baker, and Maja Matthews received common stock for consulting services related to product research, development, packaging, and marketing.
• Disposal of equipment to Epiq Scripts, LLC: On May 15, 2024, the company sold $119,819 of equipment to Epiq Scripts for $65,000, realizing a loss of $18,387.

Stakeholder Impact

• Shareholders: Face significant dilution from ongoing equity issuances (ELOC, warrant exercises, preferred stock conversions) and potential future capital raises. The increasing net losses and going concern doubt pose a high risk to investment value. The CEO's super-majority voting control over the primary operating subsidiary limits other shareholders' influence.
• Employees: Management changes, including resignations of former President and COO, may impact team stability. Equity incentive plans are in place to attract and retain talent, but the value of these awards is subject to stock price volatility.
• Customers: Product availability is limited to states where Epiq Scripts is licensed. The reliance on non-FDA approved compounded products carries inherent safety risks, which could impact customer trust and lead to product recalls or litigation. Platform transition issues have impacted revenues, suggesting potential service disruptions.
• Creditors: The company's recurring net losses and going concern doubt increase the risk for creditors. Debt conversion agreements and promissory notes with high interest rates (e.g., 18% for Tiger Cub Trust) indicate higher risk financing.
• Suppliers: Disruptions in the global supply chain or inability to find qualified vendors could impact product availability and costs. The exclusive reliance on Epiq Scripts for compounding services creates a single-point-of-failure risk.

Next Steps

• Continue to make additional and ongoing technology enhancements to the telemedicine platform.
• Further develop, market, and advertise additional men's health and wellness related products.
• Identify strategic acquisitions that complement the company's vision, funding permitting.
• Complete Phase II clinical trials and efficacy studies for patented respiratory illness prevention technology in Q1 2026.
• Prepare marketing and distribution strategy for Dermytol and commence operations in Q2 2026.
• Obtain a state pharmacy license from Alabama for Epiq Scripts, LLC by the end of Q1 2026.
• Solicit shareholder approval for the issuance of Mango & Peaches common shares and Series A shares to Jacob D. Cohen.

Key Dates

Recommendation

Mangoceuticals, Inc. is in a precarious financial position, evidenced by rapidly escalating net losses, declining revenues, and a substantial accumulated deficit, leading to a 'going concern' qualification from its auditors. The company's heavy reliance on related party transactions, particularly with its CEO, raises significant corporate governance concerns and potential conflicts of interest. While there are new product development efforts, the core compounded products are not FDA-approved, exposing the company to considerable regulatory and product liability risks. The stock has experienced extreme volatility, and ongoing capital raises, including the ELOC and preferred stock conversions, are causing substantial dilution to existing shareholders. The combination of severe financial distress, high operational risks, and governance issues makes this a high-risk investment with a strong likelihood of further value erosion.

Keywords

Men's Wellness, Telemedicine, Compounded Drugs, Erectile Dysfunction, Hair Loss, Testosterone Replacement Therapy, Weight Management, Dermytol, Respiratory Illness Prevention, SEC Filing, S-1/A, Nasdaq, MGRX, Going Concern, Dilution, Related Party Transactions, FDA Exemption, Intellectual Property, Capital Raise